CJC 1295

Growth Hormone Releasing

DESCRIPTION

CJC 1295 has been shown to increase growth hormone as well as IGF-I secretion
and it has been able to do so in very large amounts. CJC 1295 stimulates growth
hormone secretion and will keep a steady increase of HGH and IGF-1 with no
increase in prolactin, leading to fat loss, and increased protein synthesis thereby
promoting growth.

CJC 1295 is a tetrasubstituted 29-amino acid peptide hormone, primarily functioning
as a growth CJChormone1295 releasing is a tetrasubstituted hormone(GHRH)30-aminalogoacid. a peptide hormone,
primarily functioning as a growth hormone releasing hormone (GHRH) analog. with
time and the body produces anti-bodies to Sermorelin. bioconjugate with serum
albumin, thus increasing its half-life and potential therapeutic window. It
accomplishes this by using protecting groups around the amino acids of GHRH
typically susceptibledesigndo toprenzymaticvmdegradationiction. thus increasing the
half-life. Consequently CJC 1295-DAC is designed to provide a GHRH-like
stimulation around the clock. A potential drawback when using a Various
experiments have been conducted to test the pharmacokinetics of CJC 1295-DAC in
vivo and the Journal of Clinical Endocrinology & Metabolism has reported
dose-dependent increases in mean plasma GH concentrations by 2-10 fold for more
than 6 days and increased IGF-1 concentrations 1.5-3 fold for 9-11 days a er a single
injection. Mean half-life was shown to be 5.8-8.1 days, also a er multiple doses mean
IGF-1 levels remained above baseline for up to 28 days. No serious adverse
reactions were reported in any group.

PROTOCOL

Content & Potency: 1 x 2ml at 2000mcg/ml : ready-to- inject subcutaneously

Suggested dosage: 0.10ml per day 5 days out of 7 (NON-DAC) before bed, on an
empty stomach (1 month supply). Some will do multiday dosing of 0.05ml.
***We suggest using the CJC 1295 in combination with Ipamorelin as it provides a
synergistic e ect, generating ve times the bene ts of using the CJC 1295 or
Ipamorelin alone. e combination allows for the maximized release of GH because of the
CJC 1295 and Ipamorelin have di erent mechanisms of action and work on di erent
receptors (GHRH-R & Ghrelin-R).

Courtesy of: https://www.transformyouaz.com